67/100B146.710
USD
-0.21
(-0.14%)
Post Trading·146.910USD+0.200(+0.14%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.78Revenue estimate 16.29B
Q4 FY2026 · Earnings report
EPS estimate 1.78Revenue estimate 16.29B
Merck & Co financials
Yes. Merck & Co earned 2.45B USD of net income over the last twelve months, 3.6% of its revenue. It made a profit in 41 of its 41 fiscal years since 1985.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 67.30B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 2.45B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 14.75B USD
- Cash and short-term investments
- 9.65B USD
- Total debt
- 53.78B USD
- Shareholders' equityWhat is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
- 44.89B USD
Cash, debt and equity as of 30 Sept 2026.
Merck & Co earnings
Next earnings · Q4 FY2026
EPS estimate
1.78 USD
Revenue estimate
16.29B USD
Last quarter · Q3 FY2026
EPS2.49Beat +19.1%Revenue18.09BBeat +4.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 2.44 | — | — | -2.01% | 18.23B | — | — | +0.81% | |
| Q2 FY2027 | 2.09 | — | — | — | 16.84B | — | — | +1.41% | |
| Q1 FY2027 | 2.13 | — | — | — | 16.46B | — | — | +1.05% | |
| Q4 FY2026 | 1.78 | — | — | -12.75% | 16.29B | — | — | -0.65% | |
| Q3 FY2026 | 2.09 | 2.49 | +19.14% | -3.49% | 17.33B | 18.09B | +4.35% | +4.68% | |
| Q2 FY2026 | -0.27 | -0.13 | +51.94% | -106.10% | 16.37B | 16.61B | +1.45% | +5.07% | |
| Q1 FY2026 | -1.47 | -1.28 | +12.93% | -157.66% | 15.85B | 16.29B | +2.77% | +4.87% | |
| Q4 FY2025 | 2.01 | 2.04 | +1.49% | +18.60% | 16.20B | 16.40B | +1.24% | +4.97% | |
| Q3 FY2025 | 2.36 | 2.58 | +9.32% | +64.33% | 16.98B | 17.28B | +1.75% | +3.72% | |
| Q2 FY2025 | 2.03 | 2.13 | +4.93% | -6.58% | 15.86B | 15.81B | -0.37% | -1.90% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 9.92 | — | — | +11.26% | 73.58B | — | — | +6.00% |
| FY2027 | 8.91 | — | — | +222.00% | 69.42B | — | — | +3.27% |
| FY2026 | 2.77 | — | — | -69.14% | 67.22B | — | — | +3.40% |
| FY2025 | 8.93 | 8.97 | +0.40% | +17.41% | 64.85B | 65.01B | +0.25% | +1.31% |
| FY2024 | 7.53 | 7.64 | +1.48% | +409.33% | 63.99B | 64.17B | +0.29% | +6.74% |
| FY2023 | 1.38 | 1.50 | +8.93% | -79.95% | 59.97B | 60.11B | +0.24% | +1.40% |
| FY2022 | 7.39 | 7.48 | +1.16% | +19.49% | 59.12B | 59.28B | +0.27% | +21.72% |
Merck & Co growth and profitability
Full income statement- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 67.30B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 2.45B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 76.95%
- Operating margin
- 16.24%
- Net margin
- 3.64%
Revenue / Net income
Revenue Net income Net margin
How Merck & Co makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Pharmaceutical58.14B 89.6%
Animal Health6.35B 9.8%
Other Segments515.00M 0.8%
Revenue64.93B 100.0%
Cost of revenue18.20B 28.0%
Gross profit46.73B 72.0%
Research and development12.51B 19.3%
Selling and administration10.73B 16.5%
Operating income23.49B 36.2%
Tax2.80B 4.3%
Other expense2.43B 3.7%
Net income18.25B 28.1%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Merck & Co revenue breakdown
By product
FY2025
89.4%Pharmaceutical9.8%Animal Health
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Pharmaceutical | 58.14B | 89.4% | +1.3% |
| Animal Health | 6.35B | 9.8% | +8.1% |
| Other Segments | 515.00M | 0.8% | -42.2% |
By region
FY2025
56.2%United States22.4%EMEA5.2%Latin America4.6%Asia Pacific4.4%International4.2%Japan3.0%China
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 36.51B | 56.2% | +13.1% |
| EMEA | 14.58B | 22.4% | +3.8% |
| Latin America | 3.41B | 5.2% | -1.4% |
| Asia Pacific | 2.98B | 4.6% | -2.5% |
| International | 2.88B | 4.4% | +12.5% |
| Japan | 2.71B | 4.2% | -17.3% |
| China | 1.94B | 3.0% | -64.7% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Merck & Co financial health
Full balance sheet- Cash and short-term investments
- 9.65B USD
- Total debt
- 53.78B USD
- Net cash
- -44.13B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 14.75B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.35
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 1.20
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 6 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.96
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Merck & Co valuation
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 149.70
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 53.00
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 5.38
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 8.06
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 31.16
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
361.96B USD
+
Total debt
53.78B USD
−
Cash and short-term investments
9.65B USD
=
Enterprise value
406.09B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Merck & Co against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: AbbVie, Amgen, Gilead Sciences, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median149.710.7879.4
- Gross marginBelow its median72.0%70.6%76.3%Against its peers: 3 of 7Peers' median 70.9%
- Operating marginHighest in 5 years36.2%4.9%36.2%Against its peers: 2 of 7Peers' median 28.8%
- Net marginHighest in 5 years28.1%0.6%28.1%Against its peers: 3 of 7Peers' median 17.8%
- Return on equityAbove its median34.7%1.0%37.0%Against its peers: 4 of 6Peers' median 37.5%
- Free cash flow marginBelow its median19.0%15.2%28.2%Against its peers: 6 of 7Peers' median 24.3%
- Revenue growthLowest in 5 years1.2%1.2%21.7%Against its peers: 5 of 7Peers' median 4.2%
- EPS growthBelow its median8.0%-97.5%4,714.3%Against its peers: 4 of 6Peers' median 88.2%
- Debt to EBITDAAt its median1.79×1.49×5.25×Against its peers: 2 of 7Peers' median 3.16×
- Current ratioHighest in 5 years1.541.251.54Against its peers: 2 of 7Peers' median 1.15
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Merck & Co dividends
- Annual dividend
- 3.40 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 2.32%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 346.94%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 16
- Frequency
- Quarterly
- Last payment
- 0.85 USD
- Last ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 15 Sept 2026
- Last payment date
- 7 Oct 2026
Dividends per share
Merck & Co ownership
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 82.27%
- Institutional holders
- 3,954 (+39)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.90%
Who owns the shares
Institutions 82.3% Others 17.7%
As of 30 Jun 2026
Shares free to trade
Free float 2.46B shares ·99.9% Closely held 2.55M shares ·0.1%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 613.07 | 0.00 |
| Q3 2026 | 0 | 13 | 126.85K | 320.56K |
| Q2 2026 | 0 | 0 | 726.04K | 74.12K |
| Q1 2026 | 0 | 14 | 337.63K | 445.33K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Merck & Co's financials
Source: Financial Modeling Prep